The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
New draft guidance could see the agency getting ever stricter.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
Interius, one of the most advanced players, will cost $350m.